We could not find any results for:
Make sure your spelling is correct or try broadening your search.
FibroBiologics, Inc. operates as a clinical-stage cell therapy company that focuses on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs. The company develops CybroCell for degenerative disc disease; CYMS101 to... FibroBiologics, Inc. operates as a clinical-stage cell therapy company that focuses on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs. The company develops CybroCell for degenerative disc disease; CYMS101 to treat multiple sclerosis; and CYWC628 for treating wound healing. Its early-stage research programs include CYTER915 which is designed to regenerate or reinvigorate production of the thymus and/or spleen; and TCB190 for the treatment of cancers. The company was incorporated in 2021 and is based in Houston, Texas. FibroBiologics, Inc. operates as a subsidiary of Spinalcyte Llc. Show more
HOUSTON, April 25, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) ("FibroBiologics") and Charles River Laboratories (“Charles River”), a highly respected, global provider of drug...
HOUSTON, April 11, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on...
HOUSTON, April 04, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending for the...
HOUSTON, March 28, 2024 (GLOBE NEWSWIRE) -- FibroBiologics (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the...
FibroBiologics Announces Preliminary Proof of Concept for Fibroblast-based Diabetes Treatment PR Newswire HOUSTON, March 19, 2024 HOUSTON, March 19, 2024 /PRNewswire/ -- FibroBiologics, Inc...
FibroBiologics to Present at Advanced Wound Care Summit USA PR Newswire HOUSTON, March 13, 2024 HOUSTON, March 13, 2024 /PRNewswire/ -- FibroBiologics, Inc., (Nasdaq: FBLG) ("FibroBiologics"), a...
FibroBiologics Appoints Ruben A. Garcia as General Counsel PR Newswire HOUSTON, March 6, 2024 HOUSTON, March 6, 2024 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a...
FibroBiologics Files 2023 Form 10-K Annual Report PR Newswire HOUSTON, Feb. 29, 2024 HOUSTON, Feb. 29, 2024 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics") a clinical-stage...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -1 | -9.00090009001 | 11.11 | 11.7 | 9.61 | 43293 | 11.11481367 | CS |
4 | -0.72 | -6.64819944598 | 10.83 | 11.88 | 9.185 | 68917 | 10.86106846 | CS |
12 | -3.62 | -26.365622724 | 13.73 | 19.6 | 6.53 | 95434 | 12.17509691 | CS |
26 | -19.89 | -66.3 | 30 | 55 | 6.53 | 97761 | 12.55339561 | CS |
52 | -19.89 | -66.3 | 30 | 55 | 6.53 | 97761 | 12.55339561 | CS |
156 | -19.89 | -66.3 | 30 | 55 | 6.53 | 97761 | 12.55339561 | CS |
260 | -19.89 | -66.3 | 30 | 55 | 6.53 | 97761 | 12.55339561 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions